US Pharma MarketingKyowa Kirin EMEA’s Crysvita approved by EC for infants with XLH
Kyowa Kirin EMEA, a subsidiary of Kyowa Kirin, has received approval from the EC to expand the use of Crysvita for treating XLH in infants aged one month to one year across the EU and European Economic Area.
Kyowa Kirin EMEA, a subsidiary of Kyowa Kirin, has received approval from the EC to expand the use of Crysvita for treating XLH in infants aged one month to one year across the EU and European Economic Area.
Source: Pharmaceutical Technology